Feedback
Settings

Settings

Goto Application

2,522 results
Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 253
1.20200276131Delivery Agents Targeted to Degraded Elastic Fibers
US - 03.09.2020
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 16876812 Applicant CLEMSON UNIVERSITY RESEARCH FOUNDATION Inventor Naren Vyavahare

Methods and delivery agents for treatment of connective tissue that includes elastic fibers are described. Delivery agents are nano- or micro-sized particles that include a biologically active compound useful in treatment of degraded elastic fibers, and an anchoring agent at a surface that binds at or near the area of degraded elastic fibers. The delivery agents may be utilized for targeted delivery of biologically active compounds to degraded elastic fibers so as to maintain and/or regenerate the elastin component of connective tissue, and to prevent further degradation and/or rehabilitate the structural architecture of the connective tissue.

2.WO/2020/142847GALECTIN-7-SPECIFIC MONOVALENT ANTIBODIES AND USES THEREOF
WO - 16.07.2020
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
 Appl.No PCT/CA2020/050024 Applicant INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE Inventor CHATENET, David
Monovalent antibodies such as nanobodies that are specific for galectin-7 are described. These monovalent antibodies are able to interfere with the dimerization of galectin-7, and thus may be used for the treatment of diseases associated with dysregulated galectin-7 expression and/or activity, such as certain types of cancers as well as eye diseases or conditions associated with pathological neovascularization or angiogenesis.
3.WO/2020/146835MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY
WO - 16.07.2020
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/US2020/013232 Applicant MEMORIAL SLOAN KETTERING CANCER CENTER Inventor CHEUNG, Nai-Kong V.
The present disclosure relates generally to complexes comprising an interleukin-15 ("IL-15") polypeptide chain non-covalently bonded to an IL-15 receptor α-Fc fusion polypeptide ("IL-15Rα-Fc"), and multimers (e.g., trimers) thereof. The complexes of the present technology are useful in methods for enhancing immune cell function and immunotherapy in a patient in need thereof. Also provided herein are methods for preventing or treating a disease or condition in which enhancing IL-15-mediated function is beneficial (such as cancer, infectious diseases, immunodeficiencies and leukopenia) in a patient in need thereof.
4.111363047用于引起细胞内化的CD20结合免疫毒素及其使用方法
CN - 03.07.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No 202010215621.7 Applicant 分子模板公司 Inventor 埃里克·波马
本发明提供与CD20抗原结合并且将其从细胞表面位置快速内化至细胞内部的CD20结合蛋白。本发明的CD20结合蛋白包含CD20结合区和志贺菌毒素效应子区。某些公开的CD20结合蛋白杀伤在其表面表达CD20的细胞。此外，本发明公开的CD20结合蛋白可以包含另外的外源物质并且能够将这些另外的外源物质靶向递送至表达CD20的细胞的内部。此类另外的物质可以包括肽、抗原、酶和多核苷酸。这些CD20结合蛋白具有在下列各项中的用途：将其本身内化的方法，表达CD20的细胞的靶向杀伤，将外源物质递送至表达CD20的细胞中，以及治疗多种与表达CD20的细胞有关的疾病，如癌症和免疫病症。
5.WO/2020/130546HUMAN CLK2 PROTEIN-DERIVED CELL MEMBRANE-PENETRATING DOMAIN
WO - 25.06.2020
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
 Appl.No PCT/KR2019/017828 Applicant KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY Inventor KIM, Seong Jun
The present invention relates to a human CLK2 protein-derived cell membrane-penetrating domain and, more particularly, to a human CLK2 protein-derived cell membrane-penetrating domain (CLK2P cell membrane-penetrating domain) or cell-penetrating peptide, and an intracellular delivery system using same. The human CLK2 protein-derived cell membrane-penetrating domain of the present invention can be delivered intracellularly and cargo substances such as compounds, biomolecules, and various polymer materials can be delivered intracellularly using same. The CLK2P cell membrane-penetrating domain of the present invention exhibits higher cell-penetrating efficiency than that of conventional cell-penetrating peptides and is derived from human protein, and thus can prevent the occurrence of side effects and immune responses that are caused by exogenous protein-derived peptides, and accordingly, can be effectively used as a method for effectively delivering, into cells, compounds, biomolecules, and various polymer materials, which are to be applied to a human body.
6.WO/2020/122741TERNARY MICELLAR COMPLEX COMPOSED OF A SIALOGLYCOSPHINGOLIPID, A THERAPEUTICALLY ACTIVE SUBSTANCE AND AN ANTIBODY
WO - 18.06.2020
Int.Class A61K 9/107
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
 Appl.No PCT/PE2018/000033 Applicant CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) Inventor BELTRAMO, Dante Miguel
The invention relates to a pharmaceutical composition soluble in an aqueous solution, which is characterised in that it comprises sialoglycosphingolipids; polypeptides selected from the group comprising antibodies, fragments and variants of same; and at least one therapeutically active substance, forming a ternary micellar complex of sialoglycosphingolipid–therapeutically active substance–polypeptide in which the polypeptides are non-covalently associated with the micelles formed by the sialoglycosphingolipid and the therapeutically active substance.
7.WO/2020/123662FUSION PROTEIN CONSTRUCTS FOR COMPLEMENT ASSOCIATED DISEASE
WO - 18.06.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/US2019/065741 Applicant ADMIRX INC. Inventor CURTIS, Michael Steven
Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
8.WO/2020/113047ANTIBODIES CONJUGATED WITH ACTINIUM-225 AND ACTINIUM-227, AND RELATED COMPOSITIONS AND METHODS
WO - 04.06.2020
Int.Class A61K 51/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
10Antibodies or immunoglobulins; Fragments thereof
 Appl.No PCT/US2019/063668 Applicant ACTINIUM PHARMACEUTICALS, INC. Inventor LUDWIG, Dale
This invention provides a compositions of matter comprising a therapeutic protein population (such as a HuM195 antibody population) wherein (a) each therapeutic protein in the population is conjugated to one or more actinium atoms, (b) each actinium atom is either 227Ac or 225Ac, and (c) the molar ratio of 227Ac to 225Ac in the composition is at least 1:1, This invention also provides related synthetic compositions and methods, as well as methods for treating hematologic malignancies.
9.WO/2020/103910POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS
WO - 28.05.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2019/120004 Applicant IMMUNWORK INC. Inventor CHANG, Tse-Wen
The present disclosure provides a polypeptide including an anti-fibrin antibody and a serine protease moiety of human tissue plasminogen activator. Methods for treating thrombosis in a subject in need of such treatment using such polypeptide are also disclosed.
10.WO/2020/102324LIQUIDLY INJECTABLE, SELF-STABILIZING BIOPOLYMERS FOR THE DELIVERY OF RADIONUCLIDE
WO - 22.05.2020
Int.Class A61K 49/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
08characterised by the carrier
10Organic compounds
14Peptides, e.g. proteins
 Appl.No PCT/US2019/061144 Applicant DUKE UNIVERSITY Inventor CHILKOTI, Ashutosh
Described herein are compositions for liquidly injectable, self-stabilizing biopolymers for the delivery of radionuclide brachytherapy. Also described herein are methods of using the compositions.
# -